Georgetown University home page Search: Full text search Site Index: Find a web site by name or keyword Site Map: Overview of main pages Directory: Find a person; contact us About this site: Copyright, disclaimer, policies, terms of use Georgetown University home page Home page for prospective students Home page for current students Home page for alumni and alumnae Home page for family and friends Home page for faculty and staff Georgetown University Search: Full text search Site Index: Find a web site by name or keyword Site Map: Overview of main pages Directory: Find a person; contact us About this site: Copyright, disclaimer, policies, terms of use
Navigation bar Navigation bar
spacer spacer spacer spacer
border
spacer spacer spacer
border
spacer spacer

FOR IMMEDIATE RELEASE: January 3, 2012


CONTACT:

Katherine Brazauskas
202-687-2679
kcb39@georgetown.edu


Georgetown Pharmacologist V. Craig Jordan To Receive 2012 ASPET Goodman & Gilman Award


For Immediate Release
January 4, 2012

Washington, D.C. — V. Craig Jordan, OBE, PhD, DSc, FMedSci, professor of pharmacology at Georgetown University Medical Center, has been selected as the recipient of the 2012 ASPET Goodman and Gillman Award in Drug Receptor Pharmacology by the American Society for Pharmacology and Experimental Therapeutics (ASPET).

The biennial award recognizes outstanding research in the pharmacology of biological receptors. Award winners make substantial contributions to research that provide a better understanding of the mechanisms of biological processes and potentially provides the basis for the discovery of drugs useful in the treatment of diseases. Jordan was selected because of his contributions in developing the breast cancer drug tamoxifen. He was nominated by Kenneth L. Dretchen, Ph.D., chairman of the pharmacology department at Georgetown.

Jordan’s translational research established the scientific principles for the use of tamoxifen as a long-term breast cancer treatment. The drug blocks estrogen from fueling some breast cancers. Tamoxifen is a mainstay in the treatment of breast cancer, saving the lives of an estimated 400,000 women and extending the lives of millions more. Tamoxifen is also used to prevent breast cancer in women who are at an increased risk of developing the disease.

For more than 20 years, Jordan has developed and studied the evolution of drug resistance to various anti-cancer treatments. Jordan has contributed hundreds of research articles on the molecular pharmacology of tamoxifen that complement his clinical translation research. His current work on the apoptotic actions of physiological estrogen in anti-hormone-resistant breast cancer is being studied in clinical trials.

Jordan will be presented the 2012 Goodman and Gilman Award in Drug Receptor Pharmacology on Saturday, April 21 at the 2012 Annual Meeting of the American Society for Pharmacology and Experimental Therapeutics/Experimental Biology in San Diego, California.

Jordan, who also serves as scientific director at Georgetown Lombardi Comprehensive Cancer Center, has received international recognition for his pioneering studies in the adjuvant treatment and prevention of breast cancer. His contributions have been recognized by prestigious professional societies, with election to the National Academy of Sciences (2009), Fellowship of the Academy of Medical Sciences (2009) in the United Kingdom, and an honorary Fellowship of the Royal Society of Medicine and its Jephcott Gold Medal (2008). His major prizes include the St. Gallen Breast Cancer Prize (2011), the Karnofsky Award (2008), the American Cancer Society Chemoprevention Award (2006), the Charles F. Kettering Prize (2003), the American Cancer Society Medal of Honor (2002), the Bristol Myers Squibb Award (2002), and the European Institute of Oncology Breast Cancer Therapy Award (2001). In 2002, her Majesty the Queen appointed him Officer of the Most Excellent Order of the British Empire (OBE) for his contributions to International Breast Cancer Research.

About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center and Georgetown University Hospital, seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic and clinical research, patient care, community education and outreach, and the training of cancer specialists of the future. Georgetown Lombardi is one of only 40 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and the only one in the Washington, DC, area. For more information, go to http://lombardi.georgetown.edu.

About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university’s sponsored research funding. 

                                                                       ###




spacer spacer
Navigation bar Navigation bar